Macquarie Group’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Macquarie Group’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-312,314	Closed	-$30.3M	–	1990
2019 Q3	$30.3M	Sell	312,314 -178	-0.1%	-$17.8K	0.05%	367
2019 Q2	$32M	Sell	312,492 -62,654	-17%	-$6.76M	0.05%	355
2019 Q1	$42.7M	Sell	375,146 -247,243	-40%	-$18.2M	0.07%	285
2018 Q4	$24.4M	Buy	622,389 +113,533	+22%	+$4.92M	0.05%	379
2018 Q3	$27.8M	Buy	508,856 +88,931	+21%	+$6.08M	0.05%	404
2018 Q2	$34.8M	Sell	419,925 -24,179	-5%	-$1.87M	0.06%	348
2018 Q1	$29.6M	Buy	444,104 +268,834	+153%	+$15.5M	0.05%	368
2017 Q4	$9.01M	Buy	+175,270	New	+$12.6M	0.02%	656

Macquarie Group's ONCE Position: Q4 2019 in Review

Macquarie Group sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 312,314 shares — an estimated $30.3M sold.

Macquarie Group first reported a position in ONCE in Q4 2017 and held it in 8 quarters. The position peaked at $42.7M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

Macquarie Group reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Macquarie Group sold 312,314 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $30.3M.
Macquarie Group first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2017 and held it in 8 quarters.
Macquarie Group's Spark Therapeutics, Inc. Common Stock position peaked at $42.7M in Q1 2019.
0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Macquarie Group's 13F filing for Q4 2019, filed 14 Feb 2020.